3Soardi FC, Lemos-Marini SH, Coeli FB, et al. Heterozygosis for CYP21A2 mutation considered as 21- hydroxylase deficiency in neonatal screening[ J ]. Arq Bras Endocrinol Metabol,2008,52 ( 8 ) : 1388-1392.
4Van der Kamp HJ, Wit JM. Neonatal screening for congenital adrenal hyperplasia [J]. Eur J Endocrinol, 2004,151 ( Suppl 3 ) : U71-U75.
5Votava F, Torok D, Kovacs J, et al. Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia [ J ]. Eur J Endoerinol, 2005,152(6) : 869 -874.
6Gleeson HK, Wiley V, Wilcken B, et al. Two-year pilot study of newborn screening for congenital adrenal hyperplasia in New South Wales compared with nationwide case surveillance in Australia [J].J Paediatr Child Health,2008, 44 (10) :554-559.
7Grunieiro-Papendieck L, Chiesa A, Mendez V, et al. Neonatal screening for congenital adrenal hyperplasia : experience and results in Argentina [ J ]. J Pediatr Endocrinol Metab ,2008,21 ( 1 ) :73-78.
8Technical report: congenital adrenal hyperplasia. Section on endocrinology and committee on genetics [ J]. Pediatrics, 2000,106 ( 6 ) : 1511 - 1518.
9Van der Kamp HJ, Oudshoorn CG,Elvers BH, et al. Cutoff levels of 17-alpha-hydroxyprogsterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight[J].J Clin Endocrinol Metab, 2005,90 (7) :3904-3907.
